Is 4D Molecular Therapeutics Inc (FDMT) Stock About to Get Hot Thursday?

The market has been high on 4D Molecular Therapeutics Inc (FDMT) stock recently. FDMT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

4D Molecular Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FDMT!

See Full FDMT Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With FDMT Stock Today?

4D Molecular Therapeutics Inc (FDMT) stock is trading at $33.88 as of 12:02 PM on Thursday, Mar 21, a rise of $0.38, or 1.13% from the previous closing price of $33.50. The stock has traded between $33.55 and $34.28 so far today. Volume today is less active than usual. So far 129,797 shares have traded compared to average volume of 1,146,795 shares. To see InvestorsObserver's Sentiment Score for 4D Molecular Therapeutics Inc click here.

More About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Click Here to get the full Stock Report for 4D Molecular Therapeutics Inc stock.